EXPERIMENTAL STUDY OF THE TOXICITY AND HAZARD OF QUETIAPINE FUMARATE
https://doi.org/10.36946/0869-7922-2020-6-54-58
Abstract
Quetiapine is a psychotropic drug, a dibenzothiazepine derivative and a representative of the class of neuroleptics (antipsychotic drugs) of a new subgroup – atypical antipsychotic drugs («second-generation antipsychotics»). Quetiapine fumarate belongs to the 3rd hazard class in terms of DL50 when administered in the stomach according to GOST 12.1.007-76 (DL50 1380-1680 mg/kg, mice and rats), has a local irritant effect: pronounced - on the mucous membrane of the eyes and moderately pronounced - on the skin. There are no signs of skin resorptive or cumulative effects of quetiapine fumarate. When inhaled, an aerosol of quetiapine fumarate has a general toxic and irritating effect in rats. The threshold of acute inhalation action of quetiapine fumarate is set at 6,2 mg/m3 for general toxic effect (effect on the quantitative composition of peripheral blood and the cardiovascular system) and irritating effect on the mucous membranes of the upper respiratory tract. For quetiapine fumarate, the tentative safe exposure level in the air of the working area is recommended at 0,2 mg/m3 , aerosol, with «+» - special protection of the skin and eyes is required. The tentative safe exposure level in the atmospheric air of urban and rural settlements is 0,002 mg/m3.
About the Authors
M. I. Golubeva
All-Union Scientifi c Center for the Safety of Biologically Active Substances
Russian Federation
Russian Federation
Golubeva Margarita Ivanovna
142450, Staraya Kupavna, Moscow region
М. V. Bidevkina
Scientifi c Research Institute of Disinfectology of Rospotrebnadzor
Russian Federation
Russian Federation
Bidevkina Marina Vasil’evna
117246, Moscow
I. A. Bobrineva
All-Union Scientifi c Center for the Safety of Biologically Active Substances
Russian Federation
Russian Federation
Bobrineva Irina Alekseevna
142450, Staraya Kupavna, Moscow region
I. N. Razumnaya
All-Union Scientifi c Center for the Safety of Biologically Active Substances
Russian Federation
Russian Federation
Razumnaja Irina Nikolaevna
142450, Staraya Kupavna, Moscow region
E. A. Fedorova
All-Union Scientifi c Center for the Safety of Biologically Active Substances
Russian Federation
Russian Federation
Fedorova Emma Alexeеvna
142450, Staraya Kupavna, Moscow region
A. Yu. Savchenko
Scientifi c Center of Biomedical Technologies of the Federal Medical Biological Agency
Russian Federation
Russian Federation
Savchenko Аlla Jur’evna
143442, Moscow region
G. V. Ramenskaya
I.M. Sechenov First Moscow State Medical University, RF Ministry of Health
Russian Federation
Russian Federation
Ramenskaya Galina Vladislavovna
119991, Moscow
I. A. Pozharnov
AstraZeneca Industries LLC
Russian Federation
Russian Federation
Pozharnov Igor Anatol’evich
249006, Kaluga region, Borovsky district, Dobrino village
References
1. Burchinsky S.G. Problem of safety in the strategy of pharmacotherapy with atypical neuroleptics. Neuro News: Psychoneurology and neuropsychiatry. 2010; 5 (24). Available at: https:// neuronews.com.ua/ru/issuearticle-337/Problema-bezopasnostiv-strategii-farmakoterapii-atipichnymineyroleptikami#gsc.tab=0. Date of access 08.08.2019 (in Russian).
2. Maksimov V.I. Quetiapine and its place in the treatment of various diseases among the atypical psicoticos. Modern therapy of mental disorders. 2009, (2): 24-30 (in Russian).
3. Davydov A.T., Petrova N.N., Agishev V.G. Role and place of atypical antipsychotic drugs in psychiatric practice (current state of the problem). Reviews of clinical pharmacology and drug therapy. 2005, 4 (1): 38-48 (in Russian).
4. Mazo G.E., Ivanov M.V., Chomsky A.N., Lukmanova K.A. Risk of metabolic disorders in patients with schizophrenia when using atypical antipsychotics (review of literature data). Modern therapy of mental disorders. 2008, (1): 15-19 (in Russian).
5. http://www.scribd.com/doc/3553710/ SEROQUEL-quetiapine-fumarate-ProductMonograph-for-Canada. Date of Revision: May 21 2008. Date of access 08.08.2019 (in Russian).
Review
For citations:
Golubeva M.I., Bidevkina М.V., Bobrineva I.A., Razumnaya I.N., Fedorova E.A., Savchenko A.Yu., Ramenskaya G.V., Pozharnov I.A. EXPERIMENTAL STUDY OF THE TOXICITY AND HAZARD OF QUETIAPINE FUMARATE. Toxicological Review. 2020;(6):54-58. (In Russ.) https://doi.org/10.36946/0869-7922-2020-6-54-58
Views:
1084
Email this article 